PhotosBiographyFacebookTwitter

From Wikipedia, the free encyclopedia

Gerard Evan
Born (1955-08-17) 17 August 1955 (age 68) [10]
Alma mater St Peter's College, Oxford
King's College, Cambridge [10]
Known for Disease Models & Mechanisms
Awards Fellow of the Royal Society (2004)
FMedSci (1999) [1]
PhD (1982)
Scientific career
Fields Cancer [2] [3] [4] [5] [6] [7]
Disease biology
Myc regulator gene [8]
p53 tumour suppressor [9]
Institutions University of Oxford
University of Cambridge
UCSF [10] [11]
Cancer Research UK [12]
Ensemble Therapeutics
Thesis Monoclonal antibodies as reagents for the analysis of cell surfaces (1982)
Website www.bioc.cam.ac.uk/uto/evan
labmed.ucsf.edu/about/faculty/pathology-gevan.html

Gerard Ian Evan FRS, FMedSci (born 17 August 1955) is a British biologist and, since May 2022, Professor of Cancer Biology at King's College London and a principal group leader in the Francis Crick Institute. Prior to this he was Sir William Dunn Professor of Biochemistry and Head of Biochemistry at the University of Cambridge (2009-2022). [11] [13]

Education

Evan was educated at St Peter's College, Oxford, where he studied Biochemistry, and King's College, Cambridge, where he was awarded his PhD in 1982 for research using Monoclonal antibodies. [10] [14]

Research

Evan does research to the determine the molecular basis of cancer. [15] [16] [17] [18] [19] [20] [21] [22]

Career

Prior to Cambridge, Evan was Royal Society Napier Professor at University College London and the Imperial Cancer Research Fund (1988-99), then Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology, at University of California, San Francisco (1999-2011).

References

  1. ^ http://www.acmedsci.ac.uk/p59fid5303.html [ dead link]
  2. ^ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation". Molecular and Cellular Biology. 29 (19): 5306–5315. doi: 10.1128/MCB.01745-08. PMC  2747972. PMID  19635809.
  3. ^ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors". Genes & Development. 25 (16): 1746–1757. doi: 10.1101/gad.16722111. PMC  3165938. PMID  21852537.
  4. ^ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo". Cancer Cell. 14 (6): 447–457. doi: 10.1016/j.ccr.2008.10.018. PMC  2723751. PMID  19061836.
  5. ^ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment". Genes & Development. 25 (9): 907–916. doi: 10.1101/gad.2038411. PMC  3084025. PMID  21478273.
  6. ^ Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan". Disease Models and Mechanisms. 1 (2–3): 90–93. doi: 10.1242/dmm.001396. PMC  2562192. PMID  19048069.
  7. ^ Anon (2008). "Making the paper: Gerard Evan". Nature. 455 (7213): xiii. doi: 10.1038/7213xiiia. S2CID  4410691.
  8. ^ Evan, G. (2012). "Taking a Back Door to Target Myc". Science. 335 (6066): 293–294. Bibcode: 2012Sci...335..293E. doi: 10.1126/science.1217819. PMID  22267799. S2CID  26445434.
  9. ^ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer. 9 (11): 821–829. doi: 10.1038/nrc2728. PMID  19776747. S2CID  29250930.
  10. ^ a b c d "EVAN, Prof. Gerard Ian". Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press.(subscription required)
  11. ^ a b "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci". Archived from the original on 1 June 2013.
  12. ^ "Gerard Evan : Cancer Research UK". Archived from the original on 10 March 2014.
  13. ^ Gerard Evan publications indexed by Microsoft Academic
  14. ^ Evan, Gerard (1982). Monoclonal antibodies as reagents for the analysis of cell surfaces (PhD thesis). University of Cambridge.
  15. ^ Christophorou, M. A.; Ringshausen, I.; Finch, A. J.; Swigart, L. B.; Evan, G. I. (2006). "The pathological response to DNA damage does not contribute to p53-mediated tumour suppression". Nature. 443 (7108): 214–217. Bibcode: 2006Natur.443..214C. doi: 10.1038/nature05077. PMID  16957739. S2CID  4417336.
  16. ^ Junttila, M. R.; Karnezis, A. N.; Garcia, D.; Madriles, F.; Kortlever, R. M.; Rostker, F.; Brown Swigart, L.; Pham, D. M.; Seo, Y.; Evan, G. I.; Martins, C. P. (2010). "Selective activation of p53-mediated tumour suppression in high-grade tumours". Nature. 468 (7323): 567–571. Bibcode: 2010Natur.468..567J. doi: 10.1038/nature09526. PMC  3011233. PMID  21107427.
  17. ^ Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. (2008). "Modelling Myc inhibition as a cancer therapy". Nature. 455 (7213): 679–683. Bibcode: 2008Natur.455..679S. doi: 10.1038/nature07260. PMC  4485609. PMID  18716624.
  18. ^ Evan, Gerard I.; Vousden, Karen H. (2001). "Proliferation, cell cycle and apoptosis in cancer". Nature. 411 (6835): 342–348. Bibcode: 2001Natur.411..342E. doi: 10.1038/35077213. PMID  11357141. S2CID  4414024.
  19. ^ Hueber, A. O.; Zörnig, M.; Lyon, D.; Suda, T.; Nagata, S.; Evan, G. I. (1997). "Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis". Science. 278 (5341): 1305–1309. Bibcode: 1997Sci...278.1305H. doi: 10.1126/science.278.5341.1305. PMID  9360929.
  20. ^ Chittenden, T.; Harrington, E. A.; O'Connor, R.; Remington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. (1995). "Induction of apoptosis by the Bcl-2 homologue Bak". Nature. 374 (6524): 733–736. Bibcode: 1995Natur.374..733C. doi: 10.1038/374733a0. PMID  7715730. S2CID  4315947.
  21. ^ Fanidi, A.; Harrington, E. A.; Evan, G. I. (1992). "Cooperative interaction between c-myc and bcl-2 proto-oncogenes". Nature. 359 (6395): 554–556. Bibcode: 1992Natur.359..554F. doi: 10.1038/359554a0. PMID  1406976. S2CID  4247014.
  22. ^ Amati, B.; Dalton, S.; Brooks, M. W.; Littlewood, T. D.; Evan, G. I.; Land, H. (1992). "Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max". Nature. 359 (6394): 423–426. Bibcode: 1992Natur.359..423A. doi: 10.1038/359423a0. PMID  1406955. S2CID  4362486.
Academic offices
Preceded by
[[]]
Professor of Cancer Biology at King's College London
2020–present
Incumbent
From Wikipedia, the free encyclopedia

Gerard Evan
Born (1955-08-17) 17 August 1955 (age 68) [10]
Alma mater St Peter's College, Oxford
King's College, Cambridge [10]
Known for Disease Models & Mechanisms
Awards Fellow of the Royal Society (2004)
FMedSci (1999) [1]
PhD (1982)
Scientific career
Fields Cancer [2] [3] [4] [5] [6] [7]
Disease biology
Myc regulator gene [8]
p53 tumour suppressor [9]
Institutions University of Oxford
University of Cambridge
UCSF [10] [11]
Cancer Research UK [12]
Ensemble Therapeutics
Thesis Monoclonal antibodies as reagents for the analysis of cell surfaces (1982)
Website www.bioc.cam.ac.uk/uto/evan
labmed.ucsf.edu/about/faculty/pathology-gevan.html

Gerard Ian Evan FRS, FMedSci (born 17 August 1955) is a British biologist and, since May 2022, Professor of Cancer Biology at King's College London and a principal group leader in the Francis Crick Institute. Prior to this he was Sir William Dunn Professor of Biochemistry and Head of Biochemistry at the University of Cambridge (2009-2022). [11] [13]

Education

Evan was educated at St Peter's College, Oxford, where he studied Biochemistry, and King's College, Cambridge, where he was awarded his PhD in 1982 for research using Monoclonal antibodies. [10] [14]

Research

Evan does research to the determine the molecular basis of cancer. [15] [16] [17] [18] [19] [20] [21] [22]

Career

Prior to Cambridge, Evan was Royal Society Napier Professor at University College London and the Imperial Cancer Research Fund (1988-99), then Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology, at University of California, San Francisco (1999-2011).

References

  1. ^ http://www.acmedsci.ac.uk/p59fid5303.html [ dead link]
  2. ^ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation". Molecular and Cellular Biology. 29 (19): 5306–5315. doi: 10.1128/MCB.01745-08. PMC  2747972. PMID  19635809.
  3. ^ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors". Genes & Development. 25 (16): 1746–1757. doi: 10.1101/gad.16722111. PMC  3165938. PMID  21852537.
  4. ^ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo". Cancer Cell. 14 (6): 447–457. doi: 10.1016/j.ccr.2008.10.018. PMC  2723751. PMID  19061836.
  5. ^ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment". Genes & Development. 25 (9): 907–916. doi: 10.1101/gad.2038411. PMC  3084025. PMID  21478273.
  6. ^ Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan". Disease Models and Mechanisms. 1 (2–3): 90–93. doi: 10.1242/dmm.001396. PMC  2562192. PMID  19048069.
  7. ^ Anon (2008). "Making the paper: Gerard Evan". Nature. 455 (7213): xiii. doi: 10.1038/7213xiiia. S2CID  4410691.
  8. ^ Evan, G. (2012). "Taking a Back Door to Target Myc". Science. 335 (6066): 293–294. Bibcode: 2012Sci...335..293E. doi: 10.1126/science.1217819. PMID  22267799. S2CID  26445434.
  9. ^ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer. 9 (11): 821–829. doi: 10.1038/nrc2728. PMID  19776747. S2CID  29250930.
  10. ^ a b c d "EVAN, Prof. Gerard Ian". Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press.(subscription required)
  11. ^ a b "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci". Archived from the original on 1 June 2013.
  12. ^ "Gerard Evan : Cancer Research UK". Archived from the original on 10 March 2014.
  13. ^ Gerard Evan publications indexed by Microsoft Academic
  14. ^ Evan, Gerard (1982). Monoclonal antibodies as reagents for the analysis of cell surfaces (PhD thesis). University of Cambridge.
  15. ^ Christophorou, M. A.; Ringshausen, I.; Finch, A. J.; Swigart, L. B.; Evan, G. I. (2006). "The pathological response to DNA damage does not contribute to p53-mediated tumour suppression". Nature. 443 (7108): 214–217. Bibcode: 2006Natur.443..214C. doi: 10.1038/nature05077. PMID  16957739. S2CID  4417336.
  16. ^ Junttila, M. R.; Karnezis, A. N.; Garcia, D.; Madriles, F.; Kortlever, R. M.; Rostker, F.; Brown Swigart, L.; Pham, D. M.; Seo, Y.; Evan, G. I.; Martins, C. P. (2010). "Selective activation of p53-mediated tumour suppression in high-grade tumours". Nature. 468 (7323): 567–571. Bibcode: 2010Natur.468..567J. doi: 10.1038/nature09526. PMC  3011233. PMID  21107427.
  17. ^ Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. (2008). "Modelling Myc inhibition as a cancer therapy". Nature. 455 (7213): 679–683. Bibcode: 2008Natur.455..679S. doi: 10.1038/nature07260. PMC  4485609. PMID  18716624.
  18. ^ Evan, Gerard I.; Vousden, Karen H. (2001). "Proliferation, cell cycle and apoptosis in cancer". Nature. 411 (6835): 342–348. Bibcode: 2001Natur.411..342E. doi: 10.1038/35077213. PMID  11357141. S2CID  4414024.
  19. ^ Hueber, A. O.; Zörnig, M.; Lyon, D.; Suda, T.; Nagata, S.; Evan, G. I. (1997). "Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis". Science. 278 (5341): 1305–1309. Bibcode: 1997Sci...278.1305H. doi: 10.1126/science.278.5341.1305. PMID  9360929.
  20. ^ Chittenden, T.; Harrington, E. A.; O'Connor, R.; Remington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. (1995). "Induction of apoptosis by the Bcl-2 homologue Bak". Nature. 374 (6524): 733–736. Bibcode: 1995Natur.374..733C. doi: 10.1038/374733a0. PMID  7715730. S2CID  4315947.
  21. ^ Fanidi, A.; Harrington, E. A.; Evan, G. I. (1992). "Cooperative interaction between c-myc and bcl-2 proto-oncogenes". Nature. 359 (6395): 554–556. Bibcode: 1992Natur.359..554F. doi: 10.1038/359554a0. PMID  1406976. S2CID  4247014.
  22. ^ Amati, B.; Dalton, S.; Brooks, M. W.; Littlewood, T. D.; Evan, G. I.; Land, H. (1992). "Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max". Nature. 359 (6394): 423–426. Bibcode: 1992Natur.359..423A. doi: 10.1038/359423a0. PMID  1406955. S2CID  4362486.
Academic offices
Preceded by
[[]]
Professor of Cancer Biology at King's College London
2020–present
Incumbent

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook